You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PCSK9 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hemodialysis Access Failure Trial in Shanghai (pcsk9 inhibitor)

Recruiting
  • Hemodialysis Access Failure
  • pcsk9 inhibitor
  • Shanghai, Pudong, China
    Yuanyuan Xie
Sep 10, 2023

Stroke, Acute Ischemic, PCSK9 Inhibitor Trial in Seoul (Alirocumab)

Not yet recruiting
  • Stroke, Acute Ischemic
  • PCSK9 Inhibitor
  • Seoul, Korea, Republic of
    Asan Medical Center
Oct 9, 2023

PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Not yet recruiting
  • Acute Ischemic Stroke
  • (no location specified)
Nov 14, 2023

ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Trial (Evolocumab,

Not yet recruiting
  • ASCVD
  • +3 more
  • (no location specified)
Aug 3, 2023

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

Early PCSK9 Inhibitor on Ventricular Remodling Trial in Shanghai (PCSK9 inhibitor (Alirocumab)plus standard medications,

Recruiting
  • Early PCSK9 Inhibitor on Ventricular Remodling
  • PCSK9 inhibitor （Alirocumab）plus standard medications
  • standard medications
  • Shanghai, Shanghai, China
  • +1 more
May 23, 2022

Adverse Effect of Cardiovascular Medications (Diagnosis) Trial in Zibo (Evolocumab combined with statins, Statin)

Recruiting
  • Adverse Effect of Cardiovascular Medications (Diagnosis)
  • Evolocumab combined with statins
  • Statin
  • Zibo, Shandong, China
    Zibo Central Hospital
Mar 24, 2023

Lipid Metabolism, Cardiovascular Diseases Trial in Shenzhen (PCSK9 inhibitor)

Recruiting
  • Lipid Metabolism
  • Cardiovascular Diseases
  • PCSK9 inhibitor
  • Shenzhen, Guangdong, China
    Tangzhiming Li
May 4, 2022

Hypercholesterolaemia Trial (MK-0616)

Not yet recruiting
  • Hypercholesterolaemia
  • (no location specified)
Jul 12, 2023

Acute Myocardial Infarction Trial in Shanghai (alirocumab, conventional treatment)

Recruiting
  • Acute Myocardial Infarction
  • Shanghai, Shanghai, China
  • +3 more
Oct 31, 2022

Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)

Not yet recruiting
  • Arteriosclerosis
  • Hypercholesterolaemia
  • (no location specified)
Aug 17, 2023

Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention Trial in Nanjing (Placebo plus high-intensity

Not yet recruiting
  • Acute Coronary Syndrome
  • +3 more
  • Placebo plus high-intensity statin
  • PCSK 9 Inhibitor plus high-intensity statin
  • Nanjing, Jiangsu, China
    Nanjing First Hospital
Aug 1, 2022

Acute Coronary Syndrome Trial in Nanjing (Statin, PCSK9 inhibitor)

Not yet recruiting
  • Acute Coronary Syndrome
  • Nanjing, Jiangsu, China
    First Affiliated Hospital of Nanjing Medical University
Mar 17, 2022

Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)

Not yet recruiting
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • (no location specified)
Jul 10, 2023

Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)

Not yet recruiting
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • (no location specified)
Jul 10, 2023

Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder Trial in Moscow (Pitavastatin, PCSK9 inhibitor)

Recruiting
  • Dyslipidemias
  • +5 more
  • Moscow, Russian Federation
    National Medical Research Centre for Therapy and Preventive Medi
Sep 8, 2022

In-stent Restenosis, Major Adverse Cardiovascular Events Trial in Beijing (PCSK9 inhibitor, Statin)

Recruiting
  • In-stent Restenosis
  • Major Adverse Cardiovascular Events
  • Beijing, Beijing, China
    Beijing Anzhen Hospital
Jan 16, 2023

In-hospital Initiation of PCSK9 Inhibitor in Acute Myocardial

Completed
  • Coronary Disease
  • Evolocumab 140 MG/ML
  • (no location specified)
Jan 7, 2022

Hereditary Spastic Paraplegia Type 5 Trial in Fuzhou (evolocumab)

Recruiting
  • Hereditary Spastic Paraplegia Type 5
  • Fuzhou, China
    Department of Neurology , First Affiliated Hospital Fujian Medic
Nov 21, 2021

Hypercholesterolemia, Insulin Resistance, Insulin Secretion Trial in Tuebingen (Lowering cholesterol concentrations by PCSK-9

Recruiting
  • Hypercholesterolemia
  • +2 more
  • Lowering cholesterol concentrations by PCSK-9 inhibitor
  • Tuebingen, Germany
    University of Tuebingen, Department of Internal Medicine IV
Aug 24, 2022

Qualitative Features of Atherosclerotic Plaques

Active, not recruiting
  • Atherosclerotic Cardiovascular Disease
  • Riga, Latvia
    Pauls Stradins Clinical University Hospital
Dec 5, 2022

Cognitive Function in Patients Treated With PCSK9 Inhibitors

Completed
  • Cognitive Function
  • +2 more
  • PCSK9 inhibitor
  • Cee, A Coruña, Spain
  • +11 more
Jan 13, 2023

Acute Coronary Syndrome Trial (Repatha or Praluent)

Not yet recruiting
  • Acute Coronary Syndrome
  • Repatha or Praluent
  • (no location specified)
Sep 13, 2021

Prognosis of Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting
  • Ischemic Stroke
  • Large-Artery Atherosclerosis (Embolus/Thrombosis)
  • carotid artery stenting
  • +6 more
  • Wuhan, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 31, 2022

Hyperlipidemias Trial in Boston (Evolocumab, Statins (Cardiovascular Agents))

Recruiting
  • Hyperlipidemias
  • Boston, Massachusetts
    Brigham and Women's Hospital
Jul 18, 2022